Local abaloparatide administration promotes in situ alveolar bone augmentation via FAK-mediated periosteal osteogenesis
{{output}}
Insufficient alveolar bone thickness increases the risk of periodontal dehiscence and fenestration, especially in orthodontic tooth movement. Abaloparatide (ABL), a synthetic analog of human PTHrP (1-34) and a clinical medication for treating osteoporosis, has... ...
